Almost all cervical cancers are mediated by human papillomavirus infection which, when considered alongside relatively high mutation burden and expression of PD-L1, makes immunotherapy a potentially attractive treatment strategy (163, 164). This evidence concerns the gene CD274 and cervical carcinoma.